Xen 63 versus Preserflo MicroShunt implant in patients with primary open-angle glaucoma
Abstract This study compared the efficacy safety profiles of the Xen 63 and Preserflo MicroShunt devices, both standalone, in patients with primary open-angle glaucoma (POAG). It is a retrospective and single-center study conducted on consecutive on patients with medically uncontrolled POAG who unde...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2025-01-01
|
| Series: | Scientific Reports |
| Subjects: | |
| Online Access: | https://doi.org/10.1038/s41598-024-81616-3 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1841544630995255296 |
|---|---|
| author | José María Martínez-de-la-Casa Antonio Pascual-Santiago Laura Morales-Fernandez Federico Saez-Frances Sofia Garcia-Saenz Noemi Guemes-Villahoz Ruben Sanchez-Jean Carmen Mendez Julian Garcia-Feijoo |
| author_facet | José María Martínez-de-la-Casa Antonio Pascual-Santiago Laura Morales-Fernandez Federico Saez-Frances Sofia Garcia-Saenz Noemi Guemes-Villahoz Ruben Sanchez-Jean Carmen Mendez Julian Garcia-Feijoo |
| author_sort | José María Martínez-de-la-Casa |
| collection | DOAJ |
| description | Abstract This study compared the efficacy safety profiles of the Xen 63 and Preserflo MicroShunt devices, both standalone, in patients with primary open-angle glaucoma (POAG). It is a retrospective and single-center study conducted on consecutive on patients with medically uncontrolled POAG who underwent either a standalone Xen 63 or a standalone Preserflo and had a 12-month follow-up visit. The primary outcome was the mean IOP at month-12. Sixty eyes were included, 30 eyes in each Xen 63 and Preserflo groups, respectively. Preoperative IOP was significantly lowered from 20.8 ± 3.6 mmHg and 19.1 ± 3.8 mmHg to 14.2 ± 4.5 mmHg and 12.8 ± 2.3 mmHg in the Xen 63 and Preserflo groups, respectively (p < 0.0001 each, respectively); without significant differences between groups (p = 0.1346). Preoperative number of ocular-hypotensive drugs was significantly reduced from 2.3 ± 0.6 to 0.2 ± 06 drugs and from 2.3 ± 0.7 to 0.3 ± 0.6 drugs, in the Xen 63 and Preserflo groups, respectively (p < 0.0001 each, respectively); without significant differences between groups (p = 0.5212). Regarding safety, one (3.3%) eye in the Preserflo group required a device removal due to maculopathy. Three (10.0%) eyes in the Xen 63 group underwent needling. In conclusion, both the Xen 63 and the Preserflo devices effectively and safely reduced IOP and the requirement for IOP-lowering medications, exhibiting comparable IOP levels after 12 months. |
| format | Article |
| id | doaj-art-ec3244bd3e0d45f6a11322140f8f4a08 |
| institution | Kabale University |
| issn | 2045-2322 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | Scientific Reports |
| spelling | doaj-art-ec3244bd3e0d45f6a11322140f8f4a082025-01-12T12:24:17ZengNature PortfolioScientific Reports2045-23222025-01-0115111010.1038/s41598-024-81616-3Xen 63 versus Preserflo MicroShunt implant in patients with primary open-angle glaucomaJosé María Martínez-de-la-Casa0Antonio Pascual-Santiago1Laura Morales-Fernandez2Federico Saez-Frances3Sofia Garcia-Saenz4Noemi Guemes-Villahoz5Ruben Sanchez-Jean6Carmen Mendez7Julian Garcia-Feijoo8Department of Ophthalmology and ORL, Faculty of Medicine, Clinico San Carlos Hospital, Complutense University, Clinico San Carlos Hospital Health Research Institute (IdISSC)Department of Ophthalmology and ORL, Faculty of Medicine, Clinico San Carlos Hospital, Complutense University, Clinico San Carlos Hospital Health Research Institute (IdISSC)Department of Ophthalmology and ORL, Faculty of Medicine, Clinico San Carlos Hospital, Complutense University, Clinico San Carlos Hospital Health Research Institute (IdISSC)Department of Ophthalmology and ORL, Faculty of Medicine, Clinico San Carlos Hospital, Complutense University, Clinico San Carlos Hospital Health Research Institute (IdISSC)Department of Ophthalmology and ORL, Faculty of Medicine, Clinico San Carlos Hospital, Complutense University, Clinico San Carlos Hospital Health Research Institute (IdISSC)Department of Ophthalmology and ORL, Faculty of Medicine, Clinico San Carlos Hospital, Complutense University, Clinico San Carlos Hospital Health Research Institute (IdISSC)Department of Ophthalmology and ORL, Faculty of Medicine, Clinico San Carlos Hospital, Complutense University, Clinico San Carlos Hospital Health Research Institute (IdISSC)Department of Ophthalmology and ORL, Faculty of Medicine, Clinico San Carlos Hospital, Complutense University, Clinico San Carlos Hospital Health Research Institute (IdISSC)Department of Ophthalmology and ORL, Faculty of Medicine, Clinico San Carlos Hospital, Complutense University, Clinico San Carlos Hospital Health Research Institute (IdISSC)Abstract This study compared the efficacy safety profiles of the Xen 63 and Preserflo MicroShunt devices, both standalone, in patients with primary open-angle glaucoma (POAG). It is a retrospective and single-center study conducted on consecutive on patients with medically uncontrolled POAG who underwent either a standalone Xen 63 or a standalone Preserflo and had a 12-month follow-up visit. The primary outcome was the mean IOP at month-12. Sixty eyes were included, 30 eyes in each Xen 63 and Preserflo groups, respectively. Preoperative IOP was significantly lowered from 20.8 ± 3.6 mmHg and 19.1 ± 3.8 mmHg to 14.2 ± 4.5 mmHg and 12.8 ± 2.3 mmHg in the Xen 63 and Preserflo groups, respectively (p < 0.0001 each, respectively); without significant differences between groups (p = 0.1346). Preoperative number of ocular-hypotensive drugs was significantly reduced from 2.3 ± 0.6 to 0.2 ± 06 drugs and from 2.3 ± 0.7 to 0.3 ± 0.6 drugs, in the Xen 63 and Preserflo groups, respectively (p < 0.0001 each, respectively); without significant differences between groups (p = 0.5212). Regarding safety, one (3.3%) eye in the Preserflo group required a device removal due to maculopathy. Three (10.0%) eyes in the Xen 63 group underwent needling. In conclusion, both the Xen 63 and the Preserflo devices effectively and safely reduced IOP and the requirement for IOP-lowering medications, exhibiting comparable IOP levels after 12 months.https://doi.org/10.1038/s41598-024-81616-3Xen 63PreserfloMicroShuntGlaucomaMIGSIOP |
| spellingShingle | José María Martínez-de-la-Casa Antonio Pascual-Santiago Laura Morales-Fernandez Federico Saez-Frances Sofia Garcia-Saenz Noemi Guemes-Villahoz Ruben Sanchez-Jean Carmen Mendez Julian Garcia-Feijoo Xen 63 versus Preserflo MicroShunt implant in patients with primary open-angle glaucoma Scientific Reports Xen 63 Preserflo MicroShunt Glaucoma MIGS IOP |
| title | Xen 63 versus Preserflo MicroShunt implant in patients with primary open-angle glaucoma |
| title_full | Xen 63 versus Preserflo MicroShunt implant in patients with primary open-angle glaucoma |
| title_fullStr | Xen 63 versus Preserflo MicroShunt implant in patients with primary open-angle glaucoma |
| title_full_unstemmed | Xen 63 versus Preserflo MicroShunt implant in patients with primary open-angle glaucoma |
| title_short | Xen 63 versus Preserflo MicroShunt implant in patients with primary open-angle glaucoma |
| title_sort | xen 63 versus preserflo microshunt implant in patients with primary open angle glaucoma |
| topic | Xen 63 Preserflo MicroShunt Glaucoma MIGS IOP |
| url | https://doi.org/10.1038/s41598-024-81616-3 |
| work_keys_str_mv | AT josemariamartinezdelacasa xen63versuspreserflomicroshuntimplantinpatientswithprimaryopenangleglaucoma AT antoniopascualsantiago xen63versuspreserflomicroshuntimplantinpatientswithprimaryopenangleglaucoma AT lauramoralesfernandez xen63versuspreserflomicroshuntimplantinpatientswithprimaryopenangleglaucoma AT federicosaezfrances xen63versuspreserflomicroshuntimplantinpatientswithprimaryopenangleglaucoma AT sofiagarciasaenz xen63versuspreserflomicroshuntimplantinpatientswithprimaryopenangleglaucoma AT noemiguemesvillahoz xen63versuspreserflomicroshuntimplantinpatientswithprimaryopenangleglaucoma AT rubensanchezjean xen63versuspreserflomicroshuntimplantinpatientswithprimaryopenangleglaucoma AT carmenmendez xen63versuspreserflomicroshuntimplantinpatientswithprimaryopenangleglaucoma AT juliangarciafeijoo xen63versuspreserflomicroshuntimplantinpatientswithprimaryopenangleglaucoma |